ArticleJournal of clinical microbiology1998
The L1 major capsid protein of human papillomavirus type 16 variants affects yield of virus-like particles produced in an insect cell expression system.
Article in Journal of clinical microbiology, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Human Papillomavirus Minor Capsid Protein L2 Mediates Intracellular Trafficking into and Passage beyond the Endoplasmic Reticulum.Microbiology spectrum · 2022Article
- A novel C-terminal modification method enhanced the yield of human papillomavirus L1 or chimeric L1-L2 virus-like particles in the baculovirus system.Frontiers in bioengineering and biotechnology · 2022Article
- Correlation between cervical HPV DNA detection and HPV16 seroreactivity measured with L1-only and L1+L2 viral capsid antigens.Journal of medical microbiology · 2020Article
- HPV Detection in Head and Neck Squamous Cell Carcinomas: What Is the Issue?Frontiers in oncology · 2020Review
- The possible regions to design Human Papilloma Viruses vaccine in Iranian L1 protein.Biologia · 2020Article
- Naturally Occurring Single Amino Acid Substitution in the L1 Major Capsid Protein of Human Papillomavirus Type 16: Alteration of Susceptibility to Antibody-Mediated Neutralization.The Journal of infectious diseases · 2017Article
- Variants of human papillomaviruses 16 (HPV16) in Uigur women in Xinjiang, China.Infectious agents and cancer · 2016Article
- Comparative Genomics of Herpesviridae Family to Look for Potential Signatures of Human Infecting Strains.International journal of genomics · 2016Article
- Prevalence of human papillomavirus variants and genetic diversity in the L1 gene and long control region of HPV16, HPV31, and HPV58 found in North-East Brazil.BioMed research international · 2015Article
- Human papillomavirus type 16 pseudovirions with few point mutations in L1 major capsid protein FG loop could escape actual or future vaccination for potential use in gene therapy.Molecular biotechnology · 2014Article
- Human Papillomavirus Type16- L1 VLP Production in Insect Cells.Iranian journal of basic medical sciences · 2013Article
- Amino acid sequence diversity of the major human papillomavirus capsid protein: implications for current and next generation vaccines.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2013Article
- Generation of Merkel cell polyomavirus (MCV)-like particles and their application to detection of MCV antibodies.Journal of clinical microbiology · 2010Article
- Papillomavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodies.Journal of translational medicine · 2010Article
- Identification of neutralizing conformational epitopes on the human papillomavirus type 31 major capsid protein and functional implications.Protein science : a publication of the Protein Society · 2009Article
- Evolutionary dynamics of variant genomes of human papillomavirus types 18, 45, and 97.Journal of virology · 2009Article
- Specificity of L1 peptides versus virus-like particles for detection of human papillomavirus-positive cervical lesions in females attending Engativa Hospital, Bogota, Colombia.Journal of clinical microbiology · 2008Article
- Human papillomavirus type 16 variant analysis of E6, E7, and L1 genes and long control region in biopsy samples from cervical cancer patients in north India.Journal of clinical microbiology · 2008Article
- The viral etiology of AIDS-associated malignancies.Advances in pharmacology (San Diego, Calif.) · 2008Review
- Detection of human papillomavirus type 31-neutralizing antibodies from naturally infected patients by an assay based on intracellular assembly of luciferase-expressing pseudovirions.Clinical and vaccine immunology : CVI · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The L1 major capsid proteins of six human papillomavirus type 16 (HPV-16) strains were expressed in insect cells by using recombinant baculoviruses. Virus-like particles (VLPs) which appeared similar to empty virions were identified by electron microscopy for all HPV strains investigated. However, the yield of VLPs produced varied in a range from 1 to 79 depending on the HPV-16 strain. The L1 proteins of these strains differed by up to 15 amino acids from the L1 protein of the prototype HPV-16 strain. Mutations in the amino acid region from residues 83 to 97 seemed to affect the level of expression of the L1 protein. These results are important when considering the development of HPV vaccines and serological tests. They indicate that strains inducing high levels of VLP production must be selected for the development of vaccines. Moreover, the L1 proteins of all strains investigated were able to bind with DNA. We also investigated the seroreactivities of VLPs derived from three different HPV-16 strains from Algeria, Senegal, and the Philippines by testing sera from women from 11 countries in immunoglobulin G-specific enzyme-linked immunosorbent assays. We observed a strong correlation between the reactivities of the three different VLP variants, independent of the geographical origin of the sera investigated. These results indicate that the three strains investigated are serologically cross-reactive despite the fact that their L1 proteins differ in 14 amino acids and suggest that VLPs derived from only one HPV-16 strain could be sufficient for the development of an HPV-16 vaccine and anti-HPV-16 tests.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.